Complain about a product or service

Gene Mutation Spreads Breast Cancer

Researchers find mutations knock our tumor supressors

December 12, 2007

Breast Cancer • Recommended Changes to Breast Cancer Screenings Cause Controversy • Optical Biopsy Provides Surgery-Free Diagnosis • Breast Cancer Lawsuit Alleged Needless Suffering, Death • New Chemo Cocktail Blocks Breast Cancer 'Like A Fence' • Physically Fit Women Less Likely To Die Of Breast Cancer • No Link Found Between Caffeine and Breast Cancer Risk • Older Women at Greater Risk of Breast Cancer • Companies Agree To Cut Cancer-Causing Chemicals In Potato Chips • What Women -- and Men -- Should Know about Breast Cancer • Daily Aspirin May Reduce Risk of Breast Cancer • FDA Approves New Genetic Test for Breast Cancer • Gene Mutation Spreads Breast Cancer • Research Finds Green Tea Helpful Against Breast Cancer • Marijuana Compound May Fight Breast Cancer • Mayo Clinic Sees New Hope In Breast Cancer Drug • FDA Approves Evista For Reducing Breast Cancer Risk • Side Effects Drive Women from Breast Cancer Drug • Hypnosis Reduces Pain and Costs in Breast Cancer Surgery • Grapefruit Linked to Breast Cancer • Study Finds No Link Between Abortion, Miscarriage and Breast Cancer • Falling Breast Cancer Rates Linked to Declining Use of Hormone Replacement Therapy • Hispanic Women Three Times More Likely to Develop Advanced Breast Cancer • MRI Screening of Opposite Breast Necessary for Women with Breast Cancer • FDA Approves Tykerb for Advanced Breast Cancer Patients • FDA Clears New Breast Cancer Test • Needle Biopsy May Not Be Enough to Rule Out Breast Cancer in Some Cases • Red Meat May Increase Breast Cancer Risk • Breast Cancer Survivors Skipping Mammograms, Study Finds • Breast Implant Complications Frequent, Study Finds • Tests Show Drug Fights Aggressive Breast Cancer • California Sues to Require Cancer Warnings on Potato Chips and French Fries • Study Ties Fries To Breast Cancer Risk • Low-Fat Diet May Reduce Risk of Recurrent Breast Cancer • Study Suggests Pain Reliever, Breast Cancer Link • Trials Show Herceptin Aids Breast Cancer Recovery • That Pink Ribbon Can Be Misleading, Consumer Group Warns • Survival Better When Breast Cancer Detected Through Mammography

Scientists from Columbia University and Sweden’s Lund University have shed new light on how mutations of a gene – BRCA1 – can lead to breast cancer. The findings show that BRCA1 mutations can cause cancer by knocking out a powerful tumor suppressor gene known as PTEN.

The new study, to be published in Nature Genetics, was led by Ramon Parsons, M.D., Ph.D., the Avon Foundation Professor of Medicine and Pathology at Columbia University College of Physicians and Surgeons and Åke Borg, Ph.D., professor of oncology at Lund University.

“These findings are exciting because ever since the link was established between BRCA1 and breast cancer more than 10 years ago, we have been frustrated by our lack of understanding about how mutations in this gene cause breast cancer. We have been stymied by our limited resources to treat these cancers, which are associated with very poor prognoses," Parsons said. "Now that we know that PTEN is involved, we finally have a target for therapy for these cancers.”

Parsons is director of the Avon Foundation Breast Cancer Research Laboratory and director of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.

PTEN mutations promote runaway tumor cell growth by increasing the activity of a series of different proteins in the cell known as the PTEN/PI3K pathway. Shutting down any one of those proteins could potentially stop growth of the cancer. Investigational therapies to shut down proteins in the PTEN pathway are currently in Phase I clinical trials.

Parsons and his research team made the connection between BRCA1 and PTEN using techniques to search for physical chromosome breaks within the PTEN gene – a technique that had never before been used. Previous searches for PTEN mutations in BRCA1 tumors had looked for conventional mutations and failed to turn up any abnormalities.

The researchers scanned 34 biopsies taken from women with BRCA1 tumors. The PTEN gene had been split in two, but inadequately repaired in about one-third of the cancers. In some cases, entire sections of the gene were missing; in others, one-half of the gene was reattached to other regions on the chromosome.

These types of large chromosomal mistakes stem directly from the tumor’s lack of BRCA1, a gene that is normally involved in the repair of such damage. In breast cancers from women with normal BRCA1, such large mutations in PTEN were rarely detected.

Parsons estimates that about 50 percent of BRCA1 breast cancers will be found to harbor mutated PTEN once a complete analysis of chromosomal mutations is done.

Breast cancer tumors caused by BRCA1 are known as basal-like or triple-negative because these tumors usually lack estrogen, progesterone, and HER2 receptors, which are needed for most breast cancer treatments to be effective. Basal-like breast tumors are found in 10 to 20 percent of women with non-hereditary breast cancer (meaning, not caused by a genetic mutation in BRCA1 or another gene), and the researchers found that PTEN is also lost in the majority of these breast tumors as well.

“Our results point to PTEN as a major player in both hereditary and non-hereditary basal-like breast cancer, a finding that may now be exploited to develop new therapeutic strategies to improve outcomes for women with these aggressive tumors,” said Dr. Saal, who at the time of the research, was a fellow in Parsons’ Avon Foundation Breast Cancer Research Laboratory.

The researchers also predict that other cancer genes besides PTEN are targeted by BRCA1.

“By using the same techniques we used to find gross chromosomal rearrangements in PTEN, we hope to start identifying additional mutated genes involved in the development of breast cancer,” said Parsons.

“These kinds of mutations that break tumor suppressors in half may turn out to be common in many kinds of carcinomas, particularly those with deficiencies in DNA repair pathways similar to BRCA1, a question that only a systematic search can answer,” said Dr. Saal.

“Similar research is underway in tumors from carriers of germline mutations in BRCA2, the other known major breast cancer susceptibility gene,” said Dr. Borg. “BRCA2 has a role downstream in the same DNA double strand break repair pathway as BRCA1, but tumors from BRCA2 mutation carriers have a quite different phenotype compared to BRCA1 tumors, less often involving PTEN loss. However, like BRCA1, BRCA2 tumors have an instable genome with massive chromosomal aberrations, suggesting that other genes may be targeted.”

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.